U.S. markets open in 2 hours 51 minutes
  • S&P Futures

    4,044.25
    -14.50 (-0.36%)
     
  • Dow Futures

    33,320.00
    -188.00 (-0.56%)
     
  • Nasdaq Futures

    12,960.75
    -37.75 (-0.29%)
     
  • Russell 2000 Futures

    2,122.60
    -8.90 (-0.42%)
     
  • Crude Oil

    64.19
    -1.89 (-2.86%)
     
  • Gold

    1,810.30
    -12.50 (-0.69%)
     
  • Silver

    26.84
    -0.40 (-1.48%)
     
  • EUR/USD

    1.2070
    -0.0006 (-0.05%)
     
  • 10-Yr Bond

    1.6950
    0.0000 (0.00%)
     
  • Vix

    27.83
    +5.99 (+27.43%)
     
  • GBP/USD

    1.4019
    -0.0038 (-0.27%)
     
  • USD/JPY

    109.6660
    +0.0060 (+0.01%)
     
  • BTC-USD

    49,358.66
    -6,838.21 (-12.17%)
     
  • CMC Crypto 200

    1,331.30
    -232.53 (-14.87%)
     
  • FTSE 100

    6,860.83
    -143.80 (-2.05%)
     
  • Nikkei 225

    27,448.01
    -699.50 (-2.49%)
     

Asensus Surgical to Present at the H.C. Wainwright Virtual Global Life Sciences Conference

·2 min read

Asensus Surgical, Inc. (NYSE American: TRXC) (formerly TransEnterix, Inc.), a medical device company that is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery, announced today that Anthony Fernando, President and Chief Executive Officer, and Shameze Rampertab, Executive Vice President and Chief Financial Officer, will participate in the H.C. Wainwright Virtual Global Life Sciences Conference taking place March 9 and March 10, 2021.

The Company’s presentation will be available for on-demand beginning Tuesday, March 9, 2021 at 7:00 am ET.

The on-demand conference presentation will be available online on the investor relations page of the Company’s website at https://ir.asensus.com/events-and-presentations. Replays of the webcasts will be archived on the website for approximately 90 days.

About Asensus Surgical, Inc.

Asensus Surgical, Inc. is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery by unlocking the Clinical Intelligence to enable consistently superior outcomes and a new standard of surgery. This builds upon the foundation of Digital Laparoscopy with the Senhance® Surgical System powered by the Intelligent Surgical Unit™ (ISU™) to increase surgeon control and reduce surgical variability. With the addition of machine vision, augmented intelligence, and deep learning capabilities throughout the surgical experience, we intend to holistically address the current clinical, cognitive and economic shortcomings that drive surgical outcomes and value-based healthcare. Learn more about Performance-Guided Surgery and Digital Laparoscopy with the Senhance Surgical System here: www.senhance.com. Now available for sale in the US, EU, Japan, Russia, and select other countries. For a complete list of indications for use, visit: www.senhance.com/indications. For more information, visit www.asensus.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210301005217/en/

Contacts

INVESTOR CONTACT:
Mark Klausner or Mike Vallie, 443-213-0499
invest@asensus.com
or
MEDIA CONTACT:
Kristin Schaeffer
CG Life
kschaeffer@cglife.com